CRISPR Therapeutics AG
CRSP evidence brief
What we can confirm
- BioSniper Score:
- 5.8 / 10
- Market Cap:
- $5.30B
- Next Catalyst:
- Phase2_Start · Oct 31, 2026
What it means
What to watch
Prepared research question
What matters most for CRSP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRSP
CRISPR Therapeutics AG is a biotechnology company focused on developing CRISPR-based therapeutics, with the approved therapy CASGEVY as its lead asset and a pipeline spanning hemoglobinopathies, in vivo editing, CAR T approaches, and regenerative medicine.
Key risk: Cash burn rate
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 12 clinical trials · 1 catalyst for CRISPR Therapeutics AG.
CRISPR Therapeutics AG is a biotechnology company focused on developing CRISPR-based therapeutics, with the approved therapy CASGEVY as its lead asset and a pipeline spanning hemoglobinopathies, in vivo editing, CAR T approaches, and regenerative medicine.
- CRISPR Therapeutics has one approved CRISPR-based therapy, CASGEVY (exagamglogene autotemcel), developed with Vertex Pharmaceuticals, for severe sickle cell disease and transfusion-dependent beta thalassemia [pipeline].
- As of 2026-06-30, the company reported cash & equivalents of $291.3M, total revenue of $10.2M, net income of -$91.2M, shareholders' equity of $1,746.6M, and total debt of $600.0M [sec].
- The pipeline includes in vivo liver editing candidates (CTX340, CTX460, CTX321) and siRNA-based programs in collaboration with Sirius Therapeutics [sec · filed 2026-04-21].
- Zugo-cel, a next-generation CRISPR/Cas9 gene-edited CAR T cell therapy targeting CD19, has received RMAT designation from the FDA and is in Phase 1/2 trials [pipeline].
- A Phase 1/2 trial for CTX460, an in vivo liver editing candidate for alpha-1 antitrypsin deficiency, is expected to start Phase 2 on 2026-10-31 [catalyst].
What works
- CASGEVY is the first approved CRISPR-based therapy, validating the platform and providing a commercial foothold [pipeline].
- The company has a diversified pipeline spanning ex vivo, in vivo, CAR T, and siRNA modalities, reducing reliance on a single program [sec · filed 2026-04-21].
- Zugo-cel has received RMAT designation from the FDA, indicating regulatory support for its development [sec_mda · as of 2026-08-03].
- Collaborations with Vertex Pharmaceuticals and Sirius Therapeutics provide shared development costs and access to complementary technologies [sec · filed 2026-04-21].
What to weigh
- The company reported a net loss of -$91.2M for the period ending 2026-06-30, indicating ongoing operational cash burn [sec].
- Total debt of $600.0M as of 2026-06-30 represents a significant financial obligation [sec].
- CASGEVY faces competition from other gene therapies such as Zynteglo and Lyfgenia, which may limit market share [pipeline].
- Many pipeline programs are in early stages (Phase 1/2), with no guarantee of clinical or commercial success [pipeline].
From the filings
Quoted directly from source documents.
CASGEVY is an approved CRISPR-based therapy for SCD and TDT.
“CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex.”
SEC filings · April 21, 2026
Zugo-cel has RMAT designation.
“Zugo-cel has been granted regenerative medicine advanced therapy designation by the U.S. Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma.”
SEC MD&A · August 3, 2026
Catalyst timeline
- 2026-10-31 · Phase2_Start — Start of Phase 2 for CTX460, an in vivo liver editing candidate for emphysema associated with severe alpha-1 antitrypsin deficiency.
Risks & what to watch (4)›
Key risks
- Cash burn rate — Net loss of -$91.2M in the period ending 2026-06-30, with cash of $291.3M, implying a runway of roughly 3-4 quarters at current burn [sec].
- Debt burden — Total debt of $600.0M as of 2026-06-30, which may constrain financial flexibility [sec].
- Pipeline execution risk — Multiple programs are in Phase 1/2; clinical failure or delays could impair future revenue [pipeline].
- Competition for CASGEVY — Approved competitors Zynteglo and Lyfgenia may limit CASGEVY's market penetration [pipeline].
What to watch
- Commercial adoption and revenue growth of CASGEVY, as highlighted in CEO commentary from September 2026 [news · published 2026-09-14].
- Phase 2 start of CTX460 for alpha-1 antitrypsin deficiency on 2026-10-31 [catalyst].
- Progress of zugo-cel in Phase 1/2 trials and potential expansion into additional indications [sec_mda · as of 2026-08-03].
- Updates on in vivo liver editing and siRNA programs, including collaboration with Sirius Therapeutics [sec · filed 2026-04-21].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run CRISPR Therapeutics AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CRISPR Therapeutics AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.52 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~18d
0 buys · 1 sell (180d)
Catalysts
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 26.7%
- Days to cover
- 12.9
- Shares short
- 22,484,150
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRSP short interestGovernance
Frequently asked questions
What is the AI investment thesis for CRISPR Therapeutics AG?
CRISPR Therapeutics AG is a biotechnology company focused on developing CRISPR-based therapeutics, with the approved therapy CASGEVY as its lead asset and a pipeline spanning hemoglobinopathies, in vivo editing, CAR T approaches, and regenerative medicine.
What is CRISPR Therapeutics AG's next catalyst?
CRISPR Therapeutics AG's next tracked catalyst is a Phase2_Start event — "Phase2_Start: Official Title: A Phase 1/2 Multicenter, Open-label, First-in-Human Trial Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of CTX460, a Lipid Nanoparticle Formulation of SyNTase Editing Components for In Vivo Editing of the Serine Protease Inhibitor A1 (SERPINA1) Gene in Adults With Emphysema Associated With Severe Alpha-1 Antitrypsin Deficiency (AATD)" — expected October 31, 2026.
Who is the CEO of CRISPR Therapeutics AG?
Dr. Samarth Kulkarni Ph.D. is the chief executive officer of CRISPR Therapeutics AG (CRSP).
Where is CRISPR Therapeutics AG headquartered?
CRISPR Therapeutics AG (CRSP) is headquartered in Zug, Switzerland.
What therapeutic areas does CRISPR Therapeutics AG focus on?
CRISPR Therapeutics AG develops therapies across Oncology, Rare Disease, Gene Therapy, Neurology, Immunology, Cardiovascular, Metabolic, Respiratory, Dermatology, Hematology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.